{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:08:35Z","timestamp":1792177715106,"version":"4.4.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020948","name":"AstraZeneca M\u00f6lndal","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40262-025-01572-7","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T13:35:39Z","timestamp":1758202539000},"page":"1723-1735","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Population Pharmacokinetic Analysis of Balcinrenone in Healthy Participants and Participants with Heart Failure and Chronic\u00a0Kidney\u00a0Disease"],"prefix":"10.1007","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4492-5243","authenticated-orcid":false,"given":"Joanna","family":"Parkinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"\u00c5strand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Melin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Ericsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"issue":"3","key":"1572_CR1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/med.0b013e3283391989","volume":"17","author":"KC Gilbert","year":"2010","unstructured":"Gilbert KC, Brown NJ. Aldosterone and inflammation. Curr Opin Endocrinol Diabetes Obes. 2010;17(3):199\u2013204. https:\/\/doi.org\/10.1097\/med.0b013e3283391989.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"3","key":"1572_CR2","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/cphy.c130044","volume":"4","author":"E Gomez-Sanchez","year":"2014","unstructured":"Gomez-Sanchez E, Gomez-Sanchez CE. The multifaceted mineralocorticoid receptor. Compr Physiol. 2014;4(3):965\u201394. https:\/\/doi.org\/10.1002\/cphy.c130044.","journal-title":"Compr Physiol"},{"issue":"10","key":"1572_CR3","doi-asserted-by":"publisher","first-page":"P1051","DOI":"10.1038\/ki.2011.48","volume":"79","author":"J-P Bertocchio","year":"2011","unstructured":"Bertocchio J-P, Warnock DG, Jaisser F. Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. Kidney Int. 2011;79(10):P1051\u201360. https:\/\/doi.org\/10.1038\/ki.2011.48.","journal-title":"Kidney Int"},{"issue":"2","key":"1572_CR4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1161\/HYPERTENSIONAHA.114.04488","volume":"65","author":"J Bauersachs","year":"2015","unstructured":"Bauersachs J, Jaisser F, Toto R. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. J Hypertens. 2015;65(2):257\u201363. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.114.04488.","journal-title":"J Hypertens"},{"issue":"8","key":"1572_CR5","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/j.bbadis.2016.10.025","volume":"1863","author":"G Jia","year":"2017","unstructured":"Jia G, Jia Y, Sowers JR. Role of mineralocorticoid receptor activation in cardiac diastolic dysfunction. Biochim Biophys Acta Mol Basis Dis. 2017;1863(8):2012\u20138. https:\/\/doi.org\/10.1016\/j.bbadis.2016.10.025.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"10","key":"1572_CR6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709\u201317. https:\/\/doi.org\/10.1056\/NEJM199909023411001.","journal-title":"N Engl J Med"},{"issue":"1","key":"1572_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1009492.","journal-title":"N Engl J Med"},{"issue":"3","key":"1572_CR8","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.semnephrol.2014.04.008","volume":"34","author":"I Lazich","year":"2014","unstructured":"Lazich I, Bakris GL. Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. Semin Nephrol. 2014;34(3):333\u20139. https:\/\/doi.org\/10.1016\/j.semnephrol.2014.04.008.","journal-title":"Semin Nephrol"},{"issue":"2","key":"1572_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193380","volume":"13","author":"K Bamberg","year":"2018","unstructured":"Bamberg K, Johansson U, Edman K, et al. Preclinical pharmacology of AZD9977: a novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion. PLoS ONE. 2018;13(2):e0193380. https:\/\/doi.org\/10.1371\/journal.pone.0193380.","journal-title":"PLoS ONE"},{"issue":"11","key":"1572_CR10","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","volume":"7","author":"BL Neuen","year":"2019","unstructured":"Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7(11):845\u201354. https:\/\/doi.org\/10.1016\/S2213-8587(19)30256-6.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"21","key":"1572_CR11","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303.","journal-title":"N Engl J Med"},{"issue":"15","key":"1572_CR12","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"issue":"10","key":"1572_CR13","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1111\/cts.13377","volume":"15","author":"IB Squire","year":"2022","unstructured":"Squire IB, Gabrielsen A, Greasley PJ, et al. Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: a randomized trial. Clin Transl Sci. 2022;15(10):2493\u2013504. https:\/\/doi.org\/10.1111\/cts.13377.","journal-title":"Clin Transl Sci"},{"key":"1572_CR14","doi-asserted-by":"publisher","DOI":"10.22541\/au.173355686.61482895\/v1","author":"C Bhattacharya","year":"2025","unstructured":"Bhattacharya C, Ericsson H, Johansson S, et al. The effect of severe renal impairment on the pharmacokinetics, safety, and tolerability of balcinrenone. Br J Clin Pharmacol. 2025. https:\/\/doi.org\/10.22541\/au.173355686.61482895\/v1. (In Press).","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"1572_CR15","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1002\/ejhf.3294","volume":"26","author":"CSP Lam","year":"2024","unstructured":"Lam CSP, K\u00f8ber L, Kuwahara K, et al. Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: results from the phase 2b MIRACLE trial. Eur J Heart Fail. 2024;26(8):1727\u201335. https:\/\/doi.org\/10.1002\/ejhf.3294.","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"1572_CR16","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1111\/bcp.13562","volume":"84","author":"F Erlandsson","year":"2018","unstructured":"Erlandsson F, Albayaty M, Chialda L, et al. Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator. Br J Clin Pharmacol. 2018;84(7):1486\u201393. https:\/\/doi.org\/10.1111\/bcp.13562.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"1572_CR17","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1124\/dmd.122.001240","volume":"51","author":"B Lindmark","year":"2023","unstructured":"Lindmark B, Li XQ, Bhattacharya C, et al. Mass balance and absorption, distribution, metabolism, and excretion properties of balcinrenone following oral administration in combination with intravenous microtracer in healthy subjects. Drug Metab Dispos. 2023;51(8):995\u20131004. https:\/\/doi.org\/10.1124\/dmd.122.001240.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"1572_CR18","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/a:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28(5):481\u2013504. https:\/\/doi.org\/10.1023\/a:1012299115260.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"1572_CR19","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/psp4.12161","volume":"6","author":"TH Nguyen","year":"2017","unstructured":"Nguyen TH, Mouksassi MS, Holford N, et al. Model evaluation of continuous data pharmacometric models: metrics and graphics. CPT Pharmacometrics Syst Pharmacol. 2017;6(2):87\u2013109. https:\/\/doi.org\/10.1002\/psp4.12161.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"2","key":"1572_CR20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351. https:\/\/doi.org\/10.1208\/s12248-011-9255-z.","journal-title":"Aaps j"},{"issue":"9","key":"1572_CR21","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312. https:\/\/doi.org\/10.7326\/0003-4819-150-9-200905050-00006.","journal-title":"Ann Intern Med"},{"key":"1572_CR22","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/j.ejps.2017.05.056","volume":"109s","author":"NHG Holford","year":"2017","unstructured":"Holford NHG, Anderson BJ. Allometric size: the scientific theory and extension to normal fat mass. Eur J Pharm Sci. 2017;109s:S59-s64. https:\/\/doi.org\/10.1016\/j.ejps.2017.05.056.","journal-title":"Eur J Pharm Sci"},{"issue":"5","key":"1572_CR23","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/psp4.13115","volume":"13","author":"K Sanghavi","year":"2024","unstructured":"Sanghavi K, Ribbing J, Rogers JA, et al. Covariate modeling in pharmacometrics: general points for consideration. CPT Pharmacometrics Syst Pharmacol. 2024;13(5):710\u201328. https:\/\/doi.org\/10.1002\/psp4.13115.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"2","key":"1572_CR24","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/cts.12705","volume":"13","author":"A Whittaker","year":"2020","unstructured":"Whittaker A, Kragh \u00c5M, Hartleib-Geschwindner J, et al. Safety, tolerability, and pharmacokinetics of the mineralocorticoid receptor modulator AZD9977 in healthy men: a phase I multiple ascending dose study. Clin Transl Sci. 2020;13(2):275\u201383. https:\/\/doi.org\/10.1111\/cts.12705.","journal-title":"Clin Transl Sci"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01572-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01572-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01572-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T01:03:25Z","timestamp":1763168605000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01572-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1572"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01572-7","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]},"assertion":[{"value":"21 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.P., M.\u00c5., J.M., and H.E. are employees of AstraZeneca and hold stock in the company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"J.P. performed the analysis. All authors contributed to the interpretation of the data. All authors were responsible for drafting and reviewing the manuscript content and editorial decisions and approved the final version.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}},{"value":"Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca\u2019s data sharing policy described at\n                      \n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All studies were conducted in accordance with ethical principles that had their origin in the Declaration of Helsinki and were consistent with International Council for Harmonisation Good Clinical Practice and the AstraZeneca policy on Bioethics and Human Biological Samples. All participants signed the informed consent before study initiation.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}